ZeroCancer.com – fight cancer through knowledge

Cancer news

-- Breast cancer patients with low levels of vitamin D were much more likely to die of the disease or have it spread than patients getting enough of the nutrient, a study found _ adding to evidence the "sunshine vitamin" has anti-cancer benefits. The results are sure to renew arguments about whet...
An experimental drug from Swiss drugmaker Novartis slowed the progression of kidney cancer in patients whose tumors returned after initial chemotherapy, researchers reported on Friday.
Breast cancer patients with low levels of vitamin D were much more likely to die of the disease or have it spread than patients getting enough of the nutrient, a study found adding to evidence the "sunshine vitamin" has anti-cancer benefits.
FRIDAY, May 16 (HealthDay News) -- Minimally-invasive laparoscopic surgery and open surgery for colon cancer produce similar outcomes, according to researchers who reviewed findings from 12 international studies involving over 3,300 patients.
FRIDAY, May 16 (HealthDay News) -- A panel of 15 genes may help determine which patients with early-stage non-small cell lung cancer will experience a recurrence and, therefore, benefit the most from chemotherapy, a new study shows.
Just 5 percent of U.S. cancer survivors are meeting experts' recommendations on diet, physical activity and cigarette smoking, a new survey shows.
FRIDAY, May 16 (HealthDay News) -- Partnerships between major academic cancer centers and community hospitals are a quick and effective way to spread cancer treatment advances, say researchers at Fox Chase Cancer Center in Philadelphia.
FRIDAY, May 16 (HealthDay News) -- Colon cancer patients with a specific subset of the disease don't need to receive chemotherapy. In fact, not only does chemotherapy not benefit this group of patients, it may actually harm them, a new study found.
FRIDAY, May 16 (HealthDay News) -- Adults who had cancer as children or teens are more likely to experience cardiovascular disease, a new study found.
DURHAM, N.C. ? May 16, 2008 ? Patients who have had lung cancer surgery can tolerate and benefit from exercise regimens started just a month after surgery, according to a new study.

Scientists see progress in prostate cancer tests

WASHINGTON (Reuters) - Two companies have developed genetic tests that could help doctors better predict which prostate cancer patients have serious cases that need aggressive treatment.

One test, developed by Illumina Inc., was designed to help physicians tell which patients considered at medium risk will have their cancer recur after the prostate is removed. Those patients typically have a score of six or seven on the 10-point Gleason scale that is among the well-known tests for prostate cancer.

Researchers used the Illumina test to analyze prostate cancer tissue samples for 16 genes and studied how patients fared. They reported that they could use the information to give patients a score indicating whether they were likely to experience a recurrence of cancer within the next years.

If confirmed in future studies, “this information could be used to make the next leap as to what a patient should or should not have,” said Dr. Tracy Downs, a urologic oncologist at the University of California.

Another test developed by Epigenomics AG detected a gene called PITX2 and its “methylation,” a chemical alteration that controls how active a gene is. The PITX2 gene is thought to play a role in regulating hormones, which can fuel cancer expansion.

Men whose tissue samples tested positive on the Epigenomics test were three times more likely to experience cancer recurrence after having their prostate removed, the researchers reported.

“Those are the people that are really possibly good candidates for early (post-surgical) therapy,” said Susan Cottrell, a senior scientist at Epigenomics’s Seattle unit.

The company plans to seek Food and Drug Administration approval of the test if its effectiveness is confirmed in a larger research study, Cottrell said. The test could be available for use in patients “in another couple years”.

Findings on both tests were released at a meeting of the American Association for Cancer Research.

Neither test was designed to replace the Gleason score or the PSA test that doctors typically use to determine the severity of prostate cancer, the researchers said.

Prostate cancer is the most common cancer in U.S. men. It is diagnosed in 232,000 men every year and kills up to 30,000 of them. Worldwide, 221,000 men die from prostate cancer every year.

Source: Reuters

Tags:

▼ Show related feed